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1Ral Proteins and Their Structure
Ral (Ras- like) GTPases are coded for by two genes (RalA 
and RalB) which are located on human chromosomes 7 
and 2, respectively [1]. These genes were first isolated 
from a simian B- cell cDNA library by probing with an 
oligonucleotide corresponding to one of the GTP- binding 
domains of Ras [2] and named according to their sequen-
tial homology with the Ras family of small GTPases [3]. 
Although RalA and RalB are more than 85% sequence 
identical, they have distinct functions [1]. These differ-
ences may partly stem from their distinct C- terminal 
sequences, which can influence subcellular membrane 
localizations as well as effector interactions [4]. The Ral 
protein is comprised of 206 amino acids and therefore 
is slightly longer than a Ras protein (188–189 amino 
acids). Eleven additional amino acids in the N- terminal 
end and six additional amino acids in the C- terminal 
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Abstract
The Ral (Ras- Like) signaling pathway plays an important role in the biology 
of cells. A plethora of effects is regulated by this signaling pathway and its 
prooncogenic effectors. Our team has demonstrated the overactivation of the 
RalA signaling pathway in a number of human malignancies including cancers 
of the liver, ovary, lung, brain, and malignant peripheral nerve sheath tumors. 
Additionally, we have shown that the activation of RalA in cancer stem cells is 
higher in comparison with differentiated cancer cells. In this article, we review 
the role of Ral signaling in health and disease with a focus on the role of this 
multifunctional protein in the generation of therapies for cancer. An improved 
understanding of this pathway can lead to development of a novel class of 
anticancer therapies that functions on the basis of intervention with RalA or 
its downstream effectors.
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domain have been found in the Ral proteins that are not 
found in Ras proteins. However, the catalytic 
domain (5–164) of Ral and Ras proteins is highly  conserved 
[5, 6].
The bulk of the protein (180 residues) is a G- domain, 
which includes four GTP- binding motifs conserved in 
small GTPases, and an effector- binding loop which is 
involved in effector interaction. Moreover, the strongest 
identity is seen within the N- terminal 90 residues (98% 
identity) which are 100% conserved in RalA and RalB 
[4, 7]. The first 11 amino acid residues at the N- terminus 
interact with PLD or PLCδ1 [3]. These regions are called 
switch I (residues 41- 51) and switch II (residues 69–81) 
which are involved in binding to multiple targets, includ-
ing RalBP1, Sec5, Exo84, and ZONAB. These two regions 
correspond to the largest conformational changes during 
GTP- GDP cycle [5, 6]. A basic/hydrophobic amino acid- 
rich region that forms an amphipathic α- helix is found 
in the C- terminal region of RalA which has been shown 
to bind with calmodulin. A recent study has shown 
that both RalA and RalB have calcium- dependent 
calmodulin- binding sites in their C- terminal domains 
as well as calcium- independent- binding sites in their 
N- terminals [8]. The highly variable regions of RalA 
and RalB with 50% identity are in the C- terminal 
membrane- targeting sequence ending with a CAAX tetra-
peptide sequence [2, 7, 9, 10].
Both sequence and targeted mutational analysis of 
this variable region have indicated that there are unique 
phosphorylation sites for RalA or RalB which have a 
significant impact on subcellular localization and protein 
function [11, 12]. Several studies have reported that 
the two serine residues (S194 and S183) in the RalA 
C- terminus and five threonine or serine residues (T178, 
S182, S192, S193, and S198) in the RalB C- terminus are 
special targets for phosphorylation [10, 12, 13]. For 
instance, RalA can be phosphorylated on serine 194 in 
cells by Aurora Kinase A (AKA), a mitotic kinase, and 
can be dephosphorylated by protein phosphatase 2A 
(PP2A) Aβ (also known as PPP2R2B), a tumor sup-
pressor [13–15]. Recent research has shown that phos-
phorylation of RalA on S194 can favor the binding of 
RalA to RalBP1 over Sec5 and Exo84 [11]. RalB is 
phosphorylated at Ser198 by protein kinase C (PKC). 
The Ser198 site in RalB conforms to a motif recognized 
by PKC, and the mutation of this Serine to Alanine 
reduces PKC phosphorylation to approximately 70%, 
with the other 30% of phosphorylation presumably 
occurring at other sites. The phosphorylation of Ser198 
is important for anchorage- independent cell growth, cell 
motility, and actin cytoskeletal organization for in vivo 
bladder cancer tumorigenicity driven by active RalB [12]. 
These findings demonstrate that despite their extensive 
sequence identity, these Ral proteins have different 
 cellular functions.
Regulation of Ral Activity
The activation of Ral is initiated through the recruitment 
of upstream Ras- dependent or Ras- independent signaling. 
Investigations in follicular epithelial cells from human 
thyroid identified Ral as an effector of oncogenic mutant 
Ras [16]. In mammals, there are three recognized down-
stream pathways for Ras signaling (i.e., Raf, PI3K, and a 
Ral- GEFs family including RalGDS, Rgl1, Rgl2/Rif, and 
Rgl3), two of which seem to play an important role in 
the regulation of Ral activity [17, 18]. PIP3 is mediated 
upon activation of PI3K and subsequently phosphorylates 
AKT by recruiting PDK1 in the plasma membrane, which 
can then induce the activation of RAL–GEF (Ral- GDS) 
[19, 20]. Activated Ras is also linked directly to the bind-
ing and recruiting of RalGEFs to RalA and RalB small 
GTPases [21] (Fig. 1). Ral proteins can also be activated 
without Ras via RalGPS1 and RalGPS2 [22, 23]. RalGPS2 
is required for RalA activation, whereas RalGPS1 has been 
shown to be involved in the regulation of RalB [24]. Data 
show that activation of RalA is regulated by Ca2+ release 
from intracellular stores [25] and calmodulin binding [26] 
in a non- Ras- dependent manner. The results suggested by 
others [27] raise the possibility that AKA is phosphoryl-
ated by the Ca2+–calmodulin- dependent pathway that may 
control the activation of RalA in cancer and normal cells. 
The AKA not only triggers RalA activation but it may 
also play a role in regulating RalBP1 activity [15]. We 
have recently investigated the outcome of inhibition of 
AKA on RalA activation and malignant phenotype of ovar-
ian and liver cancer cells [28, 29]. Ral- GDS can also be 
activated in a non- Ras- dependent manner by cleaving the 
inactive β- arrestin–Ral- GDS protein complex in response 
to formyl- Met- Leu- Phe (fMLP) receptor stimulation [30]. 
Nitric oxide (NO) is another molecule that appears to be 
important in both Rap1 and Ral activation [31]. It is 
mentioned that both LPA1 and LPA2 receptors are associ-
ated with regulation of the small GTPase and RalA. 
Furthermore, LPA triggers RalA activation through LPA1 
[32]. Interestingly, G protein- coupled receptors (GPCRs) 
have been shown to stimulate phospholipase C and func-
tion in a Ral- dependent manner [33, 34]. Insulin- stimulated 
pathways have been identified to be crucial for Ral activa-
tion. Insulin leads to a robust activation of PI3 kinase 
which further stimulates AKT kinase activity which is able 
to inhibit the interaction of Ral- GAP complex (GAP) and 
RalA, resulting in the increase of RalA expression [35]. 
ERP57 is known to be an inhibitory regulator of the RalA 
signaling pathway which binds to and inhibits the exchange 
of GDP- inactive to GTP- bound form [36].
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Ral Effector Proteins
Activated GTP- bound Ral (Ral- GTP) was found to interact 
directly with a vast spectrum of downstream effectors 
and regulate their activation [37] (Fig. 2). In a yeast two- 
hybrid screen, RalBP1 (RLIP76), a 76 kDa Ral- binding 
protein, was discovered as the first Ral effector, which 
has regulatory function in the Ral network [38]. RalBP1 
negatively regulates the Rho family of small GTPases 
including Rac- 1 and Cdc42. Morphogenesis, actin dynam-
ics, nuclear responses, and cell cycle progression are con-
trolled by Rac- 1 and Cdc42 [38–40]. RalBP1, through a 
conserved Ral- binding domain in its C- terminal, interacts 
with the activated form of RalA and RalB [38, 41] and 
may also form a complex with the tyrosine- phosphorylated 
proteins, Reps1 (RalBP1- associated Eps homology (EH) 
domain protein 1) and Reps2/POB1 (partner of RalBP1) 
[42, 43]. Both of these proteins contain EH domains which 
exist in proteins involved in endocytosis [44]. Reps1 binds 
to Rab11- FIP2 via its EH domains [45], while POB1 binds 
to either Epsin or Eps15 to make a complex with AP2- 
clathrin [46]. Reps1 can also bind to the adaptor proteins 
like Crk and Grb2 [17] and may stimulate epidermal 
growth factor (EGF) receptor activation and lead to Ral- 
GTPases activation [42]. It has been shown that Rab11- 
FIP2 binding to Reps1 is involved in endocytosis, while 
the binding of POB1 to Epsin inhibits receptor- mediated 
endocytosis by phosphorylation of Epsin in mitosis [46, 
47]. Epsin interaction with RalBP1 can regulate its func-
tion in Arf6/Rac1- dependent pathways, leading to GTPase 
activation and ultimately promotes cell migration and 
invasion [48]. μ2, a subunit of the heterotetrameric clathrin 
adaptor (AP- 2 complex), is shown to make a complex 
with RalBP1. It is proposed that μ2 of the AP2 complex, 
like POB1 or Reps1, is involved in clathrin endocytosis 
by interacting with RalBP1 [49, 50]. RalBP1 also interacts 
with ARIP2 which regulates the endocytosis of activin by 
ActRIIs- mediated internalization through the Ral/RalBP1- 
dependent pathway [51]. The interaction between RalBP1 
and mammalian heat shock factor 1 (HSF1) results in 
the ability to regulate expression of heat shock genes in 
times of stress [52].
The binding of CDK1 to RalBP1 induces its transloca-
tion to chromosomes that contribute to terminating mitosis 
[53]. RalBP1, as a glutathione- conjugate transporter and 
an antiapoptotic protein, is necessary for chemical 
Figure 1. Downstream effectors of Ras pathway including Ral pathway and their biological roles. A series of downstream effectors of Ras exert a 
myriad of biological effects which in case of overactivation can contribute to progression toward neoplasia. Ral pathway is activated by RalGDS a 
member of RalGEF family. Although RalGDS shares sequence homology with Ras- GEFs, it does not show any affinity for Ras. Activation of PLD by Ral 
results in generation of a series of second messengers such as phosphatidic acid, lysophosphatidic acid, and diacylglycerol. Ral also activates Cdc42 
in a cross- talk with the PI3K pathway.
4 © 2017 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 
A. R. Moghadam et al.Ral Signaling in Health and Cancer
carcinogenesis, drug resistance, cancer progression, and 
spontaneous and experimental metastasis models [54–56]. 
The inhibition of transport activity of RalBP1 has been 
found to be effective for cancer cell survival by playing 
a role in stress defense mechanisms [57]. Several studies 
also revealed that RalBP1 inhibition could cause regression 
of lung, colon, prostate, kidney, and melanoma cancer 
xenografts [37, 57, 58].
Other components of the octameric exocyst complex 
are Sec5 and Exo84 [59], which are implicated in tether-
ing post- Golgi secretory vesicles to the plasma membrane 
before exocytic fusion (Spiczka et al. 2008). Sec3 and 
Exo70 associate with the exocyst subunits, thereby causing 
the maintenance of epithelial cell polarity, cytokinesis, cell 
migration, and tumor cell invasion [60]. Filamin A is 
another effector that acts via RalA. The fact that the acti-
vation of RalA may recruit cytoskeletal filamin prior to 
filopodial protrusion has been shown to be responsible 
for the formation of filopodia [61].
Ral proteins associate with phospholipase C- δ1(PLC 
δ1), and their binding is enhanced in the presence of 
Ca2+ [34]. Binding of Ral to PLC δ1 is not nucleotide- 
dependent and might stimulate G- protein- coupled recep-
tors as well as activate the nuclear- cytoplasmic shuttling 
to regulate a nuclear phosphoinositide cycle [1]. RalA 
and RalB also interact with phospholipase D (PLD) which 
is involved in multiple cellular pathways [62]. PLD1 appears 
to be present in the Golgi apparatus, endoplasmic reticu-
lum, and late endosomes, whereas PLD2 seems to be 
associated with the plasma membrane and caveolae [63]. 
PLD produces intracellular lipid messengers (PA) by 
hydrolyzing phosphatidylcholine which subsequently is 
involved in Golgi vesicle secretion and transport from 
the endoplasmic reticulum to the Golgi [64]. The Ral–PLD 
complex regulates EGF receptor endocytosis [65] and it 
is believed that Arf1 is required for this complex to stimu-
late both PLDs [66]. Furthermore, PLD activity is com-
monly increased in response to oncogenic and mitogenic 
stimuli which could be induced by Src and Ras [67].
The ZO- 1- associated nucleic acid- binding protein 
(ZONAB) has been recently described as a Ral effector 
that promotes cell proliferation and represses differentia-
tion [68, 69]. It is now clear that ZONAB functions are 
regulated by interaction between RalA and ZONAB in a 
cell density- dependent manner [70]. A model suggested 
by Frankel et al. (2005) indicated that RalA can control 
the transcriptional activity of ZONAB which is able to 
regulate gene expression. This may provide evidence 
Figure 2. RalA/B effectors. Once in GTP- bound (active) form, Ral proteins activate a collection of different effectors. Effectors such as ZONAB, Sec5, 
Exo84, Filamin, and RalBP1 are involved in a variety of biological effects such as gene transcription, cell proliferation, cell survival, and actin 
organization. PLD is involved in production of second messengers influencing activation status of a variety of transcription factors such as STAT3, 
ATF- 2, FOXO4, NFAT, c- Jun.
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showing the important contributing role of Ral to onco-
genesis by Ras [1, 70]. Although RalA and RalB have 
identical effector- binding domains, differences in their 
ability to bind specific effector proteins and subcellular 
localization allow them to carry out unique functions and 
exhibit different roles in normal and neoplastic cell func-
tion [71].
Ral Signaling in Normal Physiology
Substantial evidence now supports important physiological 
roles of Ral in normal cell function. The Ral pathway 
has been shown to be a potent player in regulating vari-
ous transcription factors. Activation of the tyrosine kinase 
Src by the Ral- GEF/Ral signaling pathway leads to the 
activation of transcription factor Stat3 and JNK kinase. 
This signal later activates c- jun kinases, a major compo-
nent of the AP- 1 transcription factor family, which stimu-
lates transcriptional activity, cell differentiation, and 
apoptosis [72–74]. Ral- mediated phosphorylation of AFX, 
a mammalian- related Forkhead transcription factor, is 
induced by PKB at T28, S193, and S258 [75]. Ral can 
also alter other transcription factors, including TCF, and 
NF- kB. However, their exact effector proteins and pathways 
are not well understood.
It is mentioned that the expression of RLIP76 protein 
was discovered in all normal tissues, but expression varied 
depending on the tissue [76]. RLIP76 binds to its protein- 
binding partners, including AP2, POB1, Reps1, epsin, and 
Rab11- FIP2 [reviewed in [71]]. Furthermore, it seems that 
RLIP76 activation functions in response to oxidative stress 
in normal cells [77]. Cellular studies also demonstrate 
that Ral- GTP- binding proteins are expressed in synaptic 
vesicles, platelet dense granules, and electromotor neurons 
[78–81]. Along with this, it has been illustrated that the 
Ral- GTPase signaling pathway is associated with cell- cycle 
G1- to S- phase progression and stimulation of cyclin D1 
gene transcription [82–84]. Recently, research has shown 
that Ral could function as an important molecule playing 
a significant role in the differentiation and self- renewal 
of hematopoietic cells [85]. However, the exact physiologic 
function of the Ral signaling pathway and its downstream 
effector proteins are still unknown.
Ral Signaling Pathways in Immune 
System
The Ral- GTPases (RalA and RalB), directly or indirectly, 
appear to be implicated in triggering diverse immune- 
signaling pathways. Both RalA and RalB have been shown 
to play crucial roles in lymphocyte function through cell- 
mediated cytotoxicity in natural killer (NK) cells [9, 86]. 
The proteins involved in Ras/Ral signaling initiate 
phosphorylation of threonines 447 and 451 which actively 
regulate AFX (acute- lymphocytic- leukemia- 1 fused gene 
from chromosome X) [75]. It has also been previously 
demonstrated that AFX is directly controlled by the PI(3)
K- PKB pathway in response to insulin only on serines 
193 and 258 [87]. In the Ras- Ral pathway, activated RalA 
triggers granule polarization and secretion in a Sec5- 
independent pathway; however, activation of RalB regulates 
only the granule secretion [86, 88]. Both RalA and RalB 
were found to be associated with secretory lysosomes (cell 
type dependent) with different functions [89, 90]. The 
involvement of Ral in the regulation of platelet dense- 
granule secretion via inhibition of Sec5- RBD is further 
supported by Kawato and coworkers [91]. Gorter et al. 
have reported a novel function for Ral that is involved 
in the regulation of BCR- induced gene transcription by 
controlling AP- 1 and NFAT activity, thereby providing 
new possibilities for Ral activity in B- cell development 
and function [92]. Gorter et al. have also demonstrated 
that Ral is activated in response to the stimulation of B 
cells and multiple myeloma (MM) cells with stromal cell- 
derived factor- 1 (SDF- 1)- controlled migration. This result 
may show the role of Ral in interfering with the control 
of SDF- 1–induced migration of B cells and MM cells 
[93].
Under the condition of virus- induced stimulation, RalB 
and Sec5 comprise a complex, recruit the innate immunity- 
signaling kinase TBK1, and trigger the IRF- 3 pathway 
leading to induction of interferon. Meanwhile, it is empha-
sized that the RalB/TBK1 pathway may activate an inflam-
matory response which can contribute to tumor promotion 
[94]. RalBP1, a main effector of Ral, is associated with 
various immune- mediated diseases. In fact, the C- terminal 
of RalBP1 is responsible for immunoreactivity [95]. 
Likewise, Ral binds to Sec5 and Exo84, and subsequently 
recruits exocyst function that is necessary for different 
cellular pathways such as polarized exocytosis, cytokinesis, 
cell migration, ciliogenesis, and wound healing [96, 97]. 
Similarly, it has been demonstrated that neutrophil dif-
ferentiation is regulated by the interaction of phospholipase 
D1 with Ral [98]. In addition, the complex of RalA and 
PLD was found to be involved in the regulation of FcγR- 
mediated phagocytosis [99]. It appears that knowing details 
about exocyst structure and function, as well as their 
relative components by using a systemic biology approach 
for the prediction of exocyst components as regulators 
of phagocytosis, will likely provide understanding of many 
aspects of innate and adaptive immunity [100].
Ral Signaling in Cancer
The oncogenic effects of Ral were discovered over two 
decades ago, expanding investigation into the tumorigenic 
6 © 2017 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 
A. R. Moghadam et al.Ral Signaling in Health and Cancer
role of Ral in a variety of different cancer types [101]. 
The chronic activation of RalA and RalB was frequently 
reported by other studies in various tumor- derived cell 
lines versus nontumorigenic counterparts, which supported 
the functional significance of Ral proteins in cancer [102–
106]. Using RNA inhibition (RNAi) of Ral protein expres-
sion, the role of Ral in cancer initiation and development 
was further supported [9, 107]. Rals regulate tumorigenesis 
and cancer progression in three ways: (1) through activa-
tion of Ral effector proteins such as RalBP1 and kinase 
Aurora A, (2) via activation of several signaling pathways 
such as phosphaolipase D1, Src, JNK, NF- kB, and cyclin 
D, and (3) by phosphorylation of Ral proteins [9, 13, 
15, 102]. Ral activation was shown to be involved in a 
number of different tumor types such as lung [105], 
colorectal [108], melanoma [109, 110], pancreatic [111], 
squamous cell carcinoma [112], hepatocellular carcinoma 
[113, 114], prostate [115], ovarian [116], bladder [12], 
chronic myelogenous leukemia [117], peripheral nerve 
sheath tumors [104], and medulloblastoma [118]. Studies 
have even been completed showing Ral- A autoantibodies 
as a potentially useful serum biomarker for prostate adeno-
carcinoma [119].
Both RalA and RalB are multifunctional proteins in 
the cancer milieu that are responsible for regulating tumor 
initiation, invasion, migration, and metastasis [3, 37, 105, 
120, 121]. Ral- GTPases have been shown to play a role 
in prostate cancer metastasis [106]. RalA and RalB col-
laborate to support pancreatic tumorigenicity through the 
regulation of tumor cell growth, invasion, and metastasis 
[102, 103]. The loss of bone metastatic activity was found 
in prostate cells that have shRNA- mediated inhibition of 
RalA expression [115]. Failure in pancreatic metastasis 
was demonstrated by Lim’s group (2005) in cells express-
ing RalB- specific shRNA through chorinic RalB depletion. 
This group also observed that RalA is activated in the 
early stage and RalB is activated in the late stage of pan-
creatic tumorigenesis [102]. RalA mRNA expression was 
reported to be enhanced in advanced stages of cancer. 
However, RalA mRNA expression was not significantly 
associated with higher tumor grade in patients with blad-
der tumors. Interestingly, the expression of both RalA 
and RalB protein levels was elevated in states of metastasis 
[122].
RalA plays a key role in RalGEF- induced transformation 
and tumorigenesis of human cells [102]. On the other 
hand, knockdown of RalA protein suppresses Ras activa-
tion or RalGEF- induced anchorage- independent growth 
[3, 102, 123]. RalB seems to be more potent than RalA 
in the regulation of cell invasion and migration [103]. 
Studies have shown that RalA plays an integral role in 
disrupting cellular adhesion via controlling Arf6 activation 
[124]. Others have suggested RalA inhibits p53, which in 
turn helps promote invasion [125]. The knockout of RalB 
leads to a decrease in the survival of transformed cells, 
cell motility, cell migration, and cell invasion [3, 123]. 
RalA and RalB are known to play a role in metastasis, 
but RalA has been postulated to play a limited role [103]. 
These experiments were performed in pancreatic, bladder, 
prostate, breast, liver, and NSCLC cells using RNAi [12, 
103, 105, 106, 113, 126]. Besides using genetic methods, 
it has been recently shown that the deletion of either 
RalA or RalB could not alter the formation of KRASG12D- 
driven tumors in a mouse model of NSCLC [127]. A 
similar result was observed for DMBA- TPA- induced skin 
carcinogenesis in a mouse model of KRASG12D- driven 
pancreatic adenocarcinoma [127]. It is assumed that the 
discrepancy between these results and prior reports may 
be caused by differences in the experimental methods 
[127].
Studies using a mouse model indicated that RalGDS 
is a putative effector molecule for Ras- driven transforma-
tion and oncogenesis [128, 129]. Activated versions of 
RalGDS have been previously shown to promote the 
metastasis of prostate cancer cells [130]. It was then found 
that inhibition of RalGDS activity can reduce the incidence 
of papillomas which leads to less aggressive behavior of 
skin cells in vivo [129]. In line with the previous find-
ings, the importance of RalGEF- Ral signaling has been 
seen in different stages of pancreatic ductal adenocarcinoma 
(PDAC) [103]. Recently, RalGDS activity was reported to 
be required for progression of colorectal and melanoma 
tumors [108–110]. Ral even appears to be required for 
promotion of tumorigenesis in tumors lacking Ras muta-
tions [104]. Zipfel’s team has demonstrated that the Ral 
signaling pathway can be activated in melanoma in the 
absence of an oncogenic Ras mutation [110]. Falsetti et al. 
(2007) have shown that geranyl geranyl transferase 1 
inhibitors (GGTI) can abolish Ral function in pancreatic 
cancer cell lines in a Ras- independent manner [123].
RalA was recently found to be phosphorylated on Ser11, 
Ser183, and Ser194. Changing phosphorylation sites could 
modulate the ability of RalA to associate with and regulate 
its downstream targets [11–13]. By using alanine substitu-
tion Aβ mutants, Ser183 and Ser194, were shown to be 
important requirements for the interaction of RalA and 
PP2A Aβ, suggesting the importance of RalA in transfor-
mation associated with loss of functional Aβ in human 
cancers [13, 15]. It has also been recognized that the 
phosphorylation of RalA at Ser183 by PKA and Ser194 
by Aurora A might represent a RAS- independent mecha-
nism of Ral regulation [131]. Similarly, the phosphorylation 
of RalB protein occurs on Ser198 by the kinase PKC 
which demonstrates the tumorigenic role of RalB through 
the promotion of internalization of the protein [12]. Thus, 
the differences in posttranslational modification in RalA 
7© 2017 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 
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and RalB might be involved in distinct subcellular locali-
zations, leading to the activation of certain effectors involved 
in malignant transformation [132]. A recent report also 
explained the regulating role of extracellular superoxide 
dismutase (SOD3) on expression of RalGEF- RGL1 in 
anaplastic thyroid cancer cells [133].
Mutations in Ral Gene
In 1986, Chardin screened λgt10 cDNA library with a 
20- mer oligonucleotide probe which corresponded to 
seven amino acids that were extremely preserved in all 
Ras member proteins from yeast to humans. He described 
a new Ras- like gene which is known as Ral [5]. Ral 
and Ras have 58% sequence homology with similar 
structural features [134]. The most similar sequence 
between them was in the guanine nucleotides region 
[135]. Oncogenic mutations in Ral’s guanine nucleotides 
region can suppress its GTPase activity. Therefore, the 
survival signal will be constitutively transmitted to the 
cell and make Ral proteins resistant to GTPase- activating 
protein (GAP) [2]. A study on human bladder cancer 
reported one missense mutation of glutamine for glu-
tamate at position 97 in the UM- UC- 6 cell line, which 
is a G- to- C transversion at nucleotide position 589, but 
it did not show any higher GTP- bound activity [122]. 
It should be mentioned that Ral activity might be affected 
by mutations of G23V and Q27L in Ras gene codons 
12 and 61 [106].
Ral genes are responsible for RalA and RalB expression 
and they are downstream effectors of Ras [11]. Although 
RalA and RalB have about 80% similarity in sequence, 
they are involved in different functions, which is primarily 
due to a 30 amino acid hypervariable region in the 
C- terminal [102, 103]. These hyper variable regions have 
a conserved CAAX motif which is targeted for protein 
prenylation [136]. Targeted mutational analysis demon-
strated that these regions have several phosphorylation 
sites that are exclusive for RalA and RalB [13]. The RalA 
C- terminus has two serine residues (S183 and S194) which 
are its unique phosphorylation sites and the RalB 
C- terminus has five threonine or serine residues (T178, 
S182, S192, S193, and S198) which can undergo phos-
phorylation [10]. Aurora A is a serine/threonine mitotic 
kinase that possesses a key role in mitosis entry, centro-
some duplication, and cytokinesis [14]. This kinase is 
mainly localized in the centrosome at different phases of 
mitosis and could be involved in tumorgenicity [137]. 
S194 in RalA is dephosphorylated by PP2A [13], but a 
mutation of S194 to alanine or dephosphorylation with 
PP2A inhibits the transforming ability of RalA [15].
Ral is activated through several mechanisms, including 
overexpression or mutations of receptor tyrosine kinases 
[138]. Furthermore, interactions between Ral and RalGEF 
can cause Ral activation.
Oncolytic Viruses and Ral Signaling
Oncolytic viruses are a promising class of replication 
competent viruses that in many cases, such as herpes 
model, have passed phase III clinical trials [139]. Reovirus 
is a benign human virus that has been under significant 
investigations including clinical trials as a cancer therapy 
agent [140–142]. Oncolytic virus therapy is based on the 
ability of viruses to effectively infect and kill tumor cells 
without harming the normal tissues. While some viruses 
seem to have a natural preference for tumor cells, most 
viruses require the modification in their tropism to spe-
cifically enter and/or replicate in cancer cells [143–147]. 
Permissiveness of cells to reovirus (a RNA oncolytic virus 
currently in advanced clinical trials [148, 149]) has been 
shown to be dependent on RalA signaling [150]. This 
was achieved by studying the permissiveness of RasV12G37 
mutant (which is only capable of signaling through 
RalGEFs) to reovirus. Additionally, inhibiting RalA by a 
dominant negative mutant induced resistance to 
reovirus.
Brain tumors are considered one of the primary targets 
for oncolytic virus therapy including reovirus therapy 
[151–153]. Malignant primary brain tumors infiltrate the 
brain tissue both near and far from the tumor. Effective 
treatment necessitates a model that can discriminate malig-
nant cells from normal tissue and then selectively kill 
those cells. Oncolytic viruses represent a model that will 
allow treatment of the tumor without affecting the rest 
of the brain. Our recent unpublished work shows that 
RalA is overactivated in glioma and medulloblastomas, 
which makes them promising targets for reovirus 
therapy.
RalA Signaling and Cancer Stem Cells
New findings in cancer biology emphasize the heterogenic 
nature of tumors. The biology of these cells, including 
their cell signaling machinery, can differ widely, resulting 
in their varying sensitivity to chemotherapy. Two major 
categories of tumor cells include cancer stem cells (CSCs) 
and differentiated cancer cells. CSCs constitute a minority 
population with enhanced tumorigenesis, invasiveness, and 
resistance to apoptosis (Fig. 3) [154–156]. Progression of 
tumors is usually correlated with higher percentage of 
cancer stem cells in the tumor cell population [157, 158]. 
Among the few methods for detecting cancer stem cells, 
such as functional assays (e.g., ALDH1 assay) or dye 
exclusion assays (dye cycle violet assay), antibody- based 
detection and sorting of surface markers (e.g., CD133, 
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CD24, CD44, etc.) is a popular method [159]. The resist-
ance of CSCs to conventional therapy and their ability 
to repopulate tumors necessitates a better understanding 
about their cell signaling features.
Interestingly, it was shown that in cancer stem cells, 
a(v)b3 integrin recruits RalB and KRAS to the plasma 
membrane resulting in the induction of TBK1 and NF- kB 
activation which contributes to the refractory status to 
erlotinib, a tyrosine kinase inhibitor [160].
Our team was interested in evaluating the level of RalA 
activation in CSC in comparison to differentiated cancer 
cells. In ovarian cancer cell lines, CD24 has been deter-
mined to serve as a marker for cancer stem cell population 
[158, 161]. Thus, we evaluated the level of RalA activation 
in CD24 high populations relative to CD24 low popula-
tions, as expression of this marker seems to follow a 
spectrum in ovarian cancer cells. We sorted these popula-
tions by flow cytometry and found a marked increase in 
RalA activation in CD24 high population [29]. Given that 
CD24 is a proven marker for cancer stem cells in ovarian 
cell populations, CD24 could provide a novel target for 
therapy.
RalA activation in lung cancer stem cells (LCSCs) was 
analyzed as well, specifically in CD44 cells, a known marker 
for LCSCs [105, 162, 163]. A549 (adenocarcinoma) cell 
population was sorted via flow cytometry according to 
high (CD44 Bright) and low CD44 (CD44 Dim) expres-
sion [105]. Once sorted, RalA activation was analyzed in 
these two cell populations. The CD44 Bright population 
had elevated RalA activation relative to the CD44 Dim 
population, suggesting RalA activation might play a major 
role in CD44+ cell biology. Again, this could provide a 
target to not only eradicate differentiated cancer cell popu-
lations but also CD44 cancer stem cell populations as 
well.
We also wanted to analyze RalA activation in cancer 
stem cell populations in hepatocellular carcinoma (HCC) 
[28]. As CD133 has been suggested to be a marker for 
HCC cancer stem cells, we analyzed expression of CD133 
in different HCC cell lines [164, 165]. We then looked 
at RalA activation as a function of CD133 expression and 
found a direct correlation between CD133 expression and 
RalA activation. Also, once HCC cells were enriched for 
CD133 +  cells, a higher level of RalA- GTP was observed 
[28]. Similar results were observed when CD133+ cells 
were sorted from primary malignant peripheral nerve 
sheath tumor (MPNST) cell population [104, 166]. While 
the level of RalA- GTP was elevated in MPNST cells as 
compared with nonmalignant Schwann cells, the expres-
sion of RalA and its activation were found to be higher 
Figure 3. Cancer stem cells and their role in cancer therapy. New concepts in cancer biology define tumors as a highly heterogenic composition of 
different cells. From developmental point of view, tumors are made of cancer stem cells (CSCs) and differentiated cancer cells. CSCs are capable of 
producing different cells that are needed to maintain tumor including differentiated cancer cells. CSCs are resistant to conventional therapies and, 
therefore, if not eradicated, they can repopulate the tumor and case a relapse. Remedies that target CSCs offer a better solution for inducing 
significant tumor regression as differentiated cancer cells have a limited lifetime.
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in CD133+ MPNST- enriched cell population in comparison 
to CD133- depleted population [166]. Finally, medullo-
blastoma CD133+ cells were also found to contain higher 
levels of RalA activation [118].
We conclude from our studies that RalA plays a sig-
nificant role in the biology of CSCs. This pathway provides 
an avenue for future research, especially as a possible 
explanation for why these populations are particularly 
resistant to therapy. The inhibition of this pathway could 
potentially serve as a novel therapeutic target in the CSC 
population.
Therapeutic Approaches Targeting Ral 
in Cancer Therapy
As inhibition of the Ras pathway has not been a promis-
ing approach in cancer therapy, a possible alternative could 
be to block this pathway indirectly by targeting downstream 
effectors of Ras, including, RalGDS, Ral, and RalBP1 [37]. 
One of the most promising approaches is targeting the 
RalGEF signaling pathways focusing on the inhibitors 
involved in Ral posttranscriptional processing and effector 
signaling. Phosphorylated GTPases have an important role 
in cancer including apoptosis inhibition, cell growth induc-
tion, invasion, and angiogenesis [167–169]. Additionally, 
protein kinases are appropriate targets for drug discovery. 
Inhibitors of GGTaseI inhibit growth in MIA- PaCa2 cells 
which induce RalB- dependent apoptosis and RalA cell- 
cycle perturbation [123]. It has been recognized that GGTI 
and Docetaxel, a chemo anticancer drug, have synergistic 
effects on the growth of prostate cancer cell lines includ-
ing LNCaP, PC3, and DU145 [169, 170]. Currently, GGTI- 
2418 is in phase I clinical trials and has shown minimal 
side effects (http://www.tigrispharma.com/).
Another interesting pattern in the regulation of G pro-
teins is phosphorylation by kinases and their localization. 
Phosphorylation of Aurora A on S194 results in relocation 
of RalA from the plasma membrane to endomembranes 
where it associates with RalBP1/RLIP76 [15]. Aurora 
inhibitors may cause RalA to be selectively inhibited. There 
are several Aurora family inhibitors such as ZM447439 
[171], Hesperadin [172], and VX- 680/MK- 0457 [173], 
which are competitors of ATP binding on Aurora mol-
ecules preventing the activation of Aurora family members. 
It has been established that VX- 680/MK- 0457 has higher 
specificity to Aurora A than two other inhibitors. However, 
Hesperadin has shown specificity to Aurora- B [171, 172]. 
Phosphorylation of S198 at the C- terminal in RalB by 
PKC in T24 or UM- UC- 3 bladder cancer cell lines can 
cause translocation of RalB from the plasma membrane 
to the perinuclear region. This induces anchorage- 
independent growth, cell migration, and lung metastasis 
[12]. Therefore, kinase inhibitors such as staurosporine 
might lead to inhibition of invasion and migration in 
human bladder carcinoma cell- line EJ [174]. Taken 
together, PKC inhibitors including Go6976 are considered 
effective molecules to inhibit metastasis due to the influ-
ence on cell- to- cell and cell- to- matrix junctions in bladder 
cancer [175]. PCK inhibitors have also shown to be effec-
tive against malignant peripheral nerve sheath tumors in 
neurofibromatosis type I [176]. In oncogenic stress situ-
ations, some apoptotic signaling pathways are activated. 
However, RalB binding to Sec5, which is a component 
of the exocyst, activates a typical IkappaB kinase family 
member TBK1. This kinase restricts initiation of apoptosis 
signaling pathways and couples with tumor cell survival 
[177]. The cyclin- dependent kinase 5 (CDK5) is linked 
to Ral function in a way that RalA and RalB activation 
and expression of Rgl2 are decreased through CDK5 inhi-
bition. Thus, CDK5 inhibitors may act as RalA and RalB 
inhibitors in pancreatic cancer [178].
Conclusion
Ral signaling pathway plays an important role in health 
and cancer. Overactivation of Ral and its signaling through 
important effectors such as RalBP1 portrays and oppor-
tunity for development of a novel class of anticancer drugs. 
Our work predicts that such anti- RalA signaling agents 
will have enhanced effects against CSCs. Such character-
istics would be of special importance as majority of our 
current anticancer agents lack significant activity against 
CSCs. Elucidation of detailed signaling components of 
this pathway can reveal new targets for treatment of human 
cancer [179, 180].
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